



February 1, 2017

## Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Alnylam Pharmaceuticals, Inc.](http://www.alnylam.com) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2016 on Wednesday, February 8, 2017, after the U.S. financial markets close.

Management will provide an update on the company and discuss fourth quarter and year-end 2016 results as well as expectations for the future via conference call on Wednesday, February 8, 2017 at 4:30 p.m. ET. To access the call, please dial 877-312-7507 (domestic) or 631-813-4828 (international) five minutes prior to the start time and refer to conference ID 57758793. A replay of the call will be available beginning at 7:30 p.m. ET on the day of the call. To access the replay, please dial 855-859-2056 (domestic) or 404-537-3406 (international), and refer to conference ID 57758793.

A live audio webcast of the call will be available on the Investors section of the company's website, [www.alnylam.com](http://www.alnylam.com). An archived webcast will be available on the Alnylam website approximately two hours after the event.

### About Alnylam Pharmaceuticals

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam's pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArS): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases. In early 2015, Alnylam launched its "Alnylam 2020" guidance for the advancement and commercialization of RNAi therapeutics as a whole new class of innovative medicines. Specifically, by the end of 2020, Alnylam expects to achieve a company profile with 3 marketed products, 10 RNAi therapeutic clinical programs - including 4 in late stages of development - across its 3 STArS. The company's demonstrated commitment to RNAi therapeutics has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascleptis, Monsanto, The Medicines Company, and Sanofi Genzyme. In addition, Alnylam holds an equity position in Regulus Therapeutics Inc., a company focused on discovery, development, and commercialization of microRNA therapeutics. Alnylam scientists and collaborators have published their research on RNAi therapeutics in over 200 peer-reviewed papers, including many in the world's top scientific journals such as *Nature*, *Nature Medicine*, *Nature Biotechnology*, *Cell*, *New England Journal of Medicine*, and *The Lancet*. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information about Alnylam's pipeline of investigational RNAi therapeutics, please visit [www.alnylam.com](http://www.alnylam.com).

View source version on [businesswire.com](http://businesswire.com): <http://www.businesswire.com/news/home/20170201005082/en/>

Alnylam Pharmaceuticals, Inc.  
Christine Regan Lindenboom, 617-682-4340  
(Investors and Media)  
or  
Josh Brodsky, 617-551-8276  
(Investors)

Source: Alnylam Pharmaceuticals, Inc.

News Provided by Acquire Media